246 related articles for article (PubMed ID: 32670884)
1. PD-L1 Expression in Glioblastoma, the Clinical and Prognostic Significance: A Systematic Literature Review and Meta-Analysis.
Hao C; Chen G; Zhao H; Li Y; Chen J; Zhang H; Li S; Zhao Y; Chen F; Li W; Jiang WG
Front Oncol; 2020; 10():1015. PubMed ID: 32670884
[No Abstract] [Full Text] [Related]
2. The prevalence and prognostic and clinicopathological value of PD-L1 and PD-L2 in renal cell carcinoma patients: a systematic review and meta-analysis involving 3,389 patients.
Lu Y; Song Y; Xu Y; Ou N; Liang Z; Hu R; Zhang W; Kang J; Wang X; Liu L; Yang Y; Liu X
Transl Androl Urol; 2020 Apr; 9(2):367-381. PubMed ID: 32420142
[TBL] [Abstract][Full Text] [Related]
3. The Clinicopathological and Prognostic Value of PD-L1 Expression in Cholangiocarcinoma: A Meta-Analysis.
Xu G; Sun L; Li Y; Xie F; Zhou X; Yang H; Du S; Xu H; Mao Y
Front Oncol; 2019; 9():897. PubMed ID: 31620360
[No Abstract] [Full Text] [Related]
4. Prognostic and Clinicopathological Role of PD-L1 in Endometrial Cancer: A Meta-Analysis.
Lu L; Li Y; Luo R; Xu J; Feng J; Wang M
Front Oncol; 2020; 10():632. PubMed ID: 32426281
[No Abstract] [Full Text] [Related]
5. The Prognostic and Clinicopathological Roles of PD-L1 Expression in Colorectal Cancer: A Systematic Review and Meta-Analysis.
Li Y; He M; Zhou Y; Yang C; Wei S; Bian X; Christopher O; Xie L
Front Pharmacol; 2019; 10():139. PubMed ID: 30873025
[No Abstract] [Full Text] [Related]
6. Prognostic and Clinicopathological Significance of PD-L1 in Patients With Bladder Cancer: A Meta-Analysis.
Zhu L; Sun J; Wang L; Li Z; Wang L; Li Z
Front Pharmacol; 2019; 10():962. PubMed ID: 31616289
[No Abstract] [Full Text] [Related]
7. The Clinicopathologic and Prognostic Significance of Programmed Cell Death Ligand 1 (PD-L1) Expression in Patients With Prostate Cancer: A Systematic Review and Meta-Analysis.
Li Y; Huang Q; Zhou Y; He M; Chen J; Gao Y; Wang X
Front Pharmacol; 2018; 9():1494. PubMed ID: 30733677
[No Abstract] [Full Text] [Related]
8. Clinicopathological and prognostic significance of programmed cell death ligand 1 (PD-L1) expression in patients with esophageal squamous cell carcinoma: a meta-analysis.
Qu HX; Zhao LP; Zhan SH; Geng CX; Xu L; Xin YN; Jiang XJ
J Thorac Dis; 2016 Nov; 8(11):3197-3204. PubMed ID: 28066599
[TBL] [Abstract][Full Text] [Related]
9. Prognostic and Clinicopathological Value of Programmed Cell Death Ligand1 Expression in Patients With Small Cell Lung Cancer: A Meta-Analysis.
Cai H; Zhang H; Jiang Y
Front Oncol; 2020; 10():1079. PubMed ID: 32670887
[No Abstract] [Full Text] [Related]
10. Prognostic value of programmed death ligand 1 (PD-L1) in glioblastoma: a systematic review, meta-analysis and validation based on dataset.
Wang H; Xiao Y; Ren X; Wan D
Bioengineered; 2021 Dec; 12(2):10366-10378. PubMed ID: 34903133
[TBL] [Abstract][Full Text] [Related]
11. Clinicopathological and prognostic significance of PD-L1 expression in sarcoma: A systematic review and meta-analysis.
Zheng C; You W; Wan P; Jiang X; Chen J; Zheng Y; Li W; Tan J; Zhang S
Medicine (Baltimore); 2018 Jun; 97(25):e11004. PubMed ID: 29923984
[TBL] [Abstract][Full Text] [Related]
12. Correlation Between PD-L2 Expression and Clinical Outcome in Solid Cancer Patients: A Meta-Analysis.
Yang H; Zhou X; Sun L; Mao Y
Front Oncol; 2019; 9():47. PubMed ID: 30891423
[No Abstract] [Full Text] [Related]
13. Predictive Values of Programmed Cell Death-Ligand 1 Expression for Prognosis, Clinicopathological Factors, and Response to Programmed Cell Death-1/Programmed Cell Death-Ligand 1 Inhibitors in Patients With Gynecological Cancers: A Meta-Analysis.
Zhang C; Yang Q
Front Oncol; 2020; 10():572203. PubMed ID: 33634012
[TBL] [Abstract][Full Text] [Related]
14. The prognostic significance of PD-L1 expression in patients with glioblastoma: A meta-analysis.
Guo X; Zhang Y; Jiao H; Miao X
Front Oncol; 2022; 12():925560. PubMed ID: 36313683
[TBL] [Abstract][Full Text] [Related]
15. The prognostic significance of PD-L1 and PD-1 expression in patients with nasopharyngeal carcinoma: a systematic review and meta-analysis.
Huang ZL; Liu S; Wang GN; Zheng SH; Ding SR; Tao YL; Chen C; Liu SR; Yang X; Chang H; Wang XH; Xia YF
Cancer Cell Int; 2019; 19():141. PubMed ID: 31139018
[TBL] [Abstract][Full Text] [Related]
16. Prognostic significance of PD-L1 in solid tumor: An updated meta-analysis.
Wang Q; Liu F; Liu L
Medicine (Baltimore); 2017 May; 96(18):e6369. PubMed ID: 28471952
[TBL] [Abstract][Full Text] [Related]
17. Clinicopathological and prognostic significance of programmed cell death ligand1 (PD-L1) expression in patients with non-small cell lung cancer: a meta-analysis.
Pan ZK; Ye F; Wu X; An HX; Wu JX
J Thorac Dis; 2015 Mar; 7(3):462-70. PubMed ID: 25922726
[TBL] [Abstract][Full Text] [Related]
18. Prognostic value of programmed cell death ligand-1 expression in ovarian cancer: an updated meta-analysis.
Piao J; Lim HJ; Lee M
Obstet Gynecol Sci; 2020 May; 63(3):346-356. PubMed ID: 32489980
[TBL] [Abstract][Full Text] [Related]
19. The prognostic value of programmed cell death ligand 1 expression in non-Hodgkin lymphoma: a meta-analysis.
Zhao S; Zhang M; Zhang Y; Meng H; Wang Y; Liu Y; Jing J; Huang L; Sun M; Zhang Y; Zhang Q
Cancer Biol Med; 2018 Aug; 15(3):290-298. PubMed ID: 30197796
[TBL] [Abstract][Full Text] [Related]
20. The predictive implication of programmed cell death ligand 1 expression in extranodal natural killer/T-Cell lymphoma and its correlation with clinicopathological features: a systematic review and meta-analysis.
Li W; Zheng Q; Luo X; Zhang X; Zheng X; Yang Y
Transl Cancer Res; 2023 Aug; 12(8):2115-2127. PubMed ID: 37701117
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
